<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2011-7582</journal-id>
<journal-title><![CDATA[Revista Colombiana de Cirugía]]></journal-title>
<abbrev-journal-title><![CDATA[rev. colomb. cir.]]></abbrev-journal-title>
<issn>2011-7582</issn>
<publisher>
<publisher-name><![CDATA[Asociación Colombiana de Cirugía]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2011-75822021000200221</article-id>
<article-id pub-id-type="doi">10.30944/20117582.836</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Diseño y validación de un nomograma pronóstico de supervivencia en pacientes con tumores neuroendocrinos primarios del apéndice cecal]]></article-title>
<article-title xml:lang="en"><![CDATA[Design and validation of a prognostic survival nomogram in patients with primary neuroendocrine tumors of the cecal appendix]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Quiroga-Centeno]]></surname>
<given-names><![CDATA[Andrea Carolina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Quiroga-Centeno]]></surname>
<given-names><![CDATA[Carlos Augusto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pastrana]]></surname>
<given-names><![CDATA[Juan Paulo Serrano]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez-Ochoa]]></surname>
<given-names><![CDATA[Sergio Alejandro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Industrial de Santander  ]]></institution>
<addr-line><![CDATA[Bucaramanga ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Industrial de Santander  ]]></institution>
<addr-line><![CDATA[Bucaramanga ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad Industrial de Santander  ]]></institution>
<addr-line><![CDATA[Bucaramanga ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,, Fundación Cardiovascular de Colombia  ]]></institution>
<addr-line><![CDATA[Floridablanca ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2021</year>
</pub-date>
<volume>36</volume>
<numero>2</numero>
<fpage>221</fpage>
<lpage>236</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S2011-75822021000200221&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S2011-75822021000200221&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S2011-75822021000200221&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción. Los tumores neuroendocrinos apendiculares (TNE-A) corresponden a la neoplasia apendicular más común. Aunque habitualmente tienen un comportamiento benigno, su potencial de extensión regional y metástasis, hacen necesario determinar de manera precisa el pronóstico de cada paciente. El objetivo del presente estudio fue diseñar y validar un nomograma pronóstico para predecir la supervivencia de los pacientes con TNE-A.  Métodos. Estudio de cohorte retrospectiva, de acuerdo a la información de la base de datos de vigilancia, epidemiología y desenlaces del Instituto Nacional de Cáncer de los Estados Unidos de América. Se incluyeron los pacientes con diagnóstico de TNE-A entre 1978 y 2016. El análisis de supervivencia se realizó mediante un modelo de regresión de Cox. Con estos resultados se construyeron los nomogramas para la supervivencia general y específica de cáncer a uno, dos, tres y cinco años. Los análisis fueron realizados en el software estadístico R (v. 3.5.3).  Resultados. Se incluyeron 3585 pacientes con diagnóstico de TNE-A, el 55,8 % fueron mujeres, y la mediana de edad fue de 49 años. El subtipo histológico más frecuente fue el Tumor de Histología Mixta (THM). La edad, el subtipo histológico, el tamaño y la extensión tumoral, fueron las únicas variables asociadas independientemente con la supervivencia después del análisis multivariado. El nomograma validado presentó una capacidad de discriminación sobresaliente para predecir tanto supervivencia general 0,81 (IC95%: 0,76-0,86), como específica a cáncer 0,88 (IC95%: 0,83 a 0,92).  Discusión. El presente estudio propone un nomograma pronóstico de supervivencia para pacientes con TNE-A, teniendo en cuenta el subtipo histológico, y alcanza una capacidad de discriminación sobresaliente para la predicción de estos desenlaces. Destacamos el peor pronóstico de los pacientes con THM, además de la supervivencia similar entre los pacientes llevados a hemicolectomía y aquellos sometidos a apendicectomía o resección del ciego, luego del análisis multivariado. Se requiere evaluar el rol de modalidades terapéuticas adyuvantes en la supervivencia de estos pacientes.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction.  Neuroendocrine tumors of the appendix (NET-A) correspond to the most common appendicular neoplasia. Although they usually have a benign behavior, their potential for regional extension and metastasis makes it necessary to accurately determine the prognosis of each patient. The objective of the present study was to design and validate a prognostic nomogram to predict survival of patients with NET-A.  Methods.  Retrospective cohort study, based on information from the surveillance, epidemiology, and outcomes database of the National Cancer Institute of the United States of America. Patients diagnosed with NET-A between 1978 and 2016 were included. Survival analysis was performed using a Cox regression model. With these results, nomograms for general and cancer-specific survival at one, two, three and five years were constructed. The analyzes were carried out in the statistical software R (v. 3.5.3).  Results.  3585 patients with a NET-A diagnosis were included, 55.8% were women, and the median age was 49 years. The most frequent histological subtype was the Mixed Histology Tumor (MHT). Age, histological subtype, size and tumor extension were the only variables independently associated with survival after multivariate analysis. The validated nomogram presented an outstanding discrimination capacity to predict both overall survival 0.81 (95% CI: 0.76-0.86) and cancer specific survival 0.88 (95% CI: 0.83 to 0.92).  Discussion.  The present study proposes a prognostic survival nomogram for patients with NET-A, taking into account the histological subtype, and achieves an outstanding discrimination capacity for the prediction of these outcomes. We highlight the poorer prognosis of patients with MHT, in addition to the similar survival between patients undergoing hemicolectomy and those undergoing appendectomy or resection of the cecum, after multivariate analysis. It is necessary to evaluate the role of adjuvant therapeutic modalities in the survival of these patients.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[nomograma]]></kwd>
<kwd lng="es"><![CDATA[tumores neuroendocrinos]]></kwd>
<kwd lng="es"><![CDATA[neoplasias del apéndice]]></kwd>
<kwd lng="es"><![CDATA[histología]]></kwd>
<kwd lng="es"><![CDATA[pronóstico]]></kwd>
<kwd lng="es"><![CDATA[supervivencia]]></kwd>
<kwd lng="en"><![CDATA[nomogram]]></kwd>
<kwd lng="en"><![CDATA[neuroendocrine tumors]]></kwd>
<kwd lng="en"><![CDATA[neoplasms of the appendix]]></kwd>
<kwd lng="en"><![CDATA[histology]]></kwd>
<kwd lng="en"><![CDATA[prognosis]]></kwd>
<kwd lng="en"><![CDATA[survival]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moertel]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
<name>
<surname><![CDATA[Weiland]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Nagorney]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Dockerty]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carcinoid tumor of the appendix: Treatment and prognosis]]></article-title>
<source><![CDATA[N Engl J Med.]]></source>
<year>1987</year>
<volume>317</volume>
<page-range>1699-701</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mosquera]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fitzgerald]]></surname>
<given-names><![CDATA[TL]]></given-names>
</name>
<name>
<surname><![CDATA[Vora]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Grzybowski]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Novel nomogram combining depth of invasion and size can accurately predict the risk for regional nodal metastases for appendiceal neuroendocrine tumors (A-NET)]]></article-title>
<source><![CDATA[J Surg Oncol.]]></source>
<year>2017</year>
<volume>116</volume>
<page-range>651-7</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pinto]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz Medel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Carrillo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Retamal]]></surname>
<given-names><![CDATA[IN]]></given-names>
</name>
<name>
<surname><![CDATA[Bravo]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Valenzuela]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chilean registry for neuroendocrine tumors: A Latin American perspective]]></article-title>
<source><![CDATA[Horm Cancer.]]></source>
<year>2019</year>
<volume>10</volume>
<page-range>3-10</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dasari]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Shen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Halperin]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States]]></article-title>
<source><![CDATA[JAMA Oncol.]]></source>
<year>2017</year>
<volume>3</volume>
<page-range>1335</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abdelaal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[El Ansari]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Bozom]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Khawar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Shahid]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Aleter]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frequency, characteristics and outcomes of appendicular neuroendocrine tumors: A cross-sectional study from an academic tertiary care hospital]]></article-title>
<source><![CDATA[Ann Med Surg.]]></source>
<year>2017</year>
<volume>21</volume>
<page-range>20-4</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Galanopoulos]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Toumpanakis]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The problem of appendiceal carcinoids]]></article-title>
<source><![CDATA[Endocrinol Metab Clin North Am.]]></source>
<year>2018</year>
<volume>47</volume>
<page-range>661-9</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Taggart]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
<name>
<surname><![CDATA[Abraham]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Overman]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Mansfield]]></surname>
<given-names><![CDATA[PF]]></given-names>
</name>
<name>
<surname><![CDATA[Rashid]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Goblet cell carcinoid tumor, mixed goblet cell carcinoid-adenocarcinoma, and adenocarcinoma of the appendix: comparison of clinicopathologic features and prognosis]]></article-title>
<source><![CDATA[Arch Pathol Lab Med.]]></source>
<year>2015</year>
<volume>139</volume>
<page-range>782-90</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Balachandran]]></surname>
<given-names><![CDATA[VP]]></given-names>
</name>
<name>
<surname><![CDATA[Gonen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[DeMatteo]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nomograms in oncology: more than meets the eye]]></article-title>
<source><![CDATA[Lancet Oncol.]]></source>
<year>2015</year>
<volume>16</volume>
<page-range>e173-80</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vickers]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cronin]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Everything you always wanted to know about evaluating prediction models (but were too afraid to ask)]]></article-title>
<source><![CDATA[Urology.]]></source>
<year>2010</year>
<volume>76</volume>
<page-range>1298</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amr]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Froghi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Edmond]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Haq]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Thengungal Kochupapy]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management and outcomes of appendicular neuroendocrine tumours: Retrospective review with 5-year follow-up]]></article-title>
<source><![CDATA[Eur J Surg Oncol EJSO.]]></source>
<year>2015</year>
<volume>41</volume>
<page-range>1243-6</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rindi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Arnold]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bosman]]></surname>
<given-names><![CDATA[FT]]></given-names>
</name>
<name>
<surname><![CDATA[Capella]]></surname>
<given-names><![CDATA[FT]]></given-names>
</name>
<name>
<surname><![CDATA[Klimstra]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Kloppel]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nomenclature and classification of neuroendocrine neoplasms of the digestive system]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Bosman]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
<name>
<surname><![CDATA[Hruban]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Theise]]></surname>
<given-names><![CDATA[ND]]></given-names>
</name>
</person-group>
<source><![CDATA[WHO Classification of Tumours of the Digestive System]]></source>
<year>2010</year>
<publisher-loc><![CDATA[Lyon ]]></publisher-loc>
<publisher-name><![CDATA[International Agency for Research on Cancer (IARC)]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Groth]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Virnig]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Refaie]]></surname>
<given-names><![CDATA[WB]]></given-names>
</name>
<name>
<surname><![CDATA[Jarosek]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Jensen]]></surname>
<given-names><![CDATA[EH]]></given-names>
</name>
<name>
<surname><![CDATA[Tuttle]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Appendiceal carcinoid tumors: Predictors of lymph node metastasis and the impact of right hemicolectomy on survival]]></article-title>
<source><![CDATA[J Surg Oncol.]]></source>
<year>2011</year>
<volume>103</volume>
<page-range>39-45</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sarshekeh]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Advani]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Halperin]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Conrad]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Shen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Yao]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Regional lymph node involvement and outcomes in appendiceal neuroendocrine tumors: a SEER database analysis]]></article-title>
<source><![CDATA[Oncotarget.]]></source>
<year>2017</year>
<volume>8</volume>
<page-range>99541-51</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ciarrocchi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pietroletti]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Carlei]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Necozione]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Amicucci]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Propensity adjusted appraisal of the surgical strategy for appendiceal carcinoids]]></article-title>
<source><![CDATA[Tech Coloproctology.]]></source>
<year>2015</year>
<volume>19</volume>
<page-range>35-41</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mullen]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Savarese]]></surname>
<given-names><![CDATA[DMF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carcinoid tumors of the appendix: A population-based study: Carcinoid Tumors of the Appendix]]></article-title>
<source><![CDATA[J Surg Oncol.]]></source>
<year>2011</year>
<volume>104</volume>
<page-range>41-4</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pape]]></surname>
<given-names><![CDATA[U-F]]></given-names>
</name>
<name>
<surname><![CDATA[Perren]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Niederle]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Gross]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gress]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ENETS Consensus guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas]]></article-title>
<source><![CDATA[Neuroendocrinology.]]></source>
<year>2012</year>
<volume>95</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>135-56</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kunz]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
<name>
<surname><![CDATA[Reidy-Lagunes]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Anthony]]></surname>
<given-names><![CDATA[LB]]></given-names>
</name>
<name>
<surname><![CDATA[Bertino]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Brendtro]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consensus guidelines for the management and treatment of neuroendocrine tumors]]></article-title>
<source><![CDATA[Pancreas.]]></source>
<year>2013</year>
<volume>42</volume>
<page-range>557-77</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="">
<collab>National Comprehensive Cancer Network</collab>
<source><![CDATA[NCCN clinical practice guidelines in oncology: neuroendocrine tumors, Version 2.2016]]></source>
<year></year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
